arrow
D

Daniel R. Zwahlen

cantonal hospital winterthur
H指数:32
被引数:3,149

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial

剂量强化与常规剂量挽救性放疗治疗前列腺切除术后生物化学复发性前列腺癌:SAKK 09/10随机III期试验的长期数据

2026-01-050
OAAI
Skin cancer and hyperthermia and radiotherapy - SAHARA: study protocol for a multicenter, two-arm, open-label, randomized controlled phase II non-inferiority trial

皮肤癌、高热疗法和放射疗法——SAHARA:一项多中心、双臂、开放标签、随机对照的II期非劣效性试验研究方案

2025-12-010
OAAI
Long-term urinary continence and influencing factors after salvage radiotherapy: results of the SAKK 09/10 dose escalation trial

根治性放疗后长期尿失禁及其影响因素:SAKK 09/10剂量递增试验结果

2025-07-080
PRE
Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials

预测前列腺癌放疗剂量反应:NRG/RTOG 0126和SAKK 09/10随机III期试验中辐射特征验证

2025-02-010
OAAI
ASO Visual Abstract: Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
2023-11-130
PRE
Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
2023-10-305
OAAI
Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
2023-06-253
OAAI
Trends in neoadjuvant systemic therapy rates in Europe: Pre-planned substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
2023-03-010
PRE
Axillary dissection to determine nodal burden to inform systemic therapy recommendations in patients with clinically node-positive breast cancer: Pre-planned substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
2023-03-010
PRE